Reich K - Search Results

1

Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data.

Gottlieb AB, Deodhar A, Mcinnes IB, Baraliakos X, Reich K, Schreiber S, Bao W, Marfo K, Richards HB, Pricop L, Shete A, Trivedi V, Keefe D, Papavassilis CC, Jagiello P, Papanastasiou P, Mease PJ, Lebwohl M. Gottlieb AB, et al. Among authors: reich k. Acta Derm Venereol. 2022 Apr 27;102:adv00698. doi: 10.2340/actadv.v102.563. Acta Derm Venereol. 2022. PMID: 35146532 Free PMC article.

2

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).

Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, Guzzo C, Hsu MC, Wang Y, Li S, Dooley LT, Reich K; PHOENIX 2 study investigators. Papp KA, et al. Among authors: reich k. Lancet. 2008 May 17;371(9625):1675-84. doi: 10.1016/S0140-6736(08)60726-6. Lancet. 2008. PMID: 18486740 Clinical Trial.

3

Alefacept with methotrexate for treatment of psoriatic arthritis: open-label extension of a randomized, double-blind, placebo-controlled study.

Mease PJ, Reich K; Alefacept in Psoriatic Arthritis Study Group. Mease PJ, et al. Among authors: reich k. J Am Acad Dermatol. 2009 Mar;60(3):402-11. doi: 10.1016/j.jaad.2008.09.050. Epub 2008 Nov 25. J Am Acad Dermatol. 2009. PMID: 19028407 Clinical Trial.

4

Adverse drug events in infliximab-treated patients compared with the general and psoriasis populations.

Menter A, Reich K, Gottlieb AB, Bala M, Li S, Hsu MC, Guzzo C, Diels J, Gelfand JM. Menter A, et al. Among authors: reich k. J Drugs Dermatol. 2008 Dec;7(12):1137-46. J Drugs Dermatol. 2008. PMID: 19137767

5

Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations.

Lebwohl M, Yeilding N, Szapary P, Wang Y, Li S, Zhu Y, Reich K, Langley RG, Papp KA. Lebwohl M, et al. Among authors: reich k. J Am Acad Dermatol. 2010 Oct;63(4):571-9. doi: 10.1016/j.jaad.2009.11.012. J Am Acad Dermatol. 2010. PMID: 20599293 Clinical Trial.

6

Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies.

Reich K, Langley RG, Lebwohl M, Szapary P, Guzzo C, Yeilding N, Li S, Hsu MC, Griffiths CE. Reich K, et al. Br J Dermatol. 2011 Apr;164(4):862-72. doi: 10.1111/j.1365-2133.2011.10257.x. Br J Dermatol. 2011. PMID: 21332467 Clinical Trial.

7

The long-term safety of adalimumab treatment in moderate to severe psoriasis: a comprehensive analysis of all adalimumab exposure in all clinical trials.

Leonardi C, Papp K, Strober B, Reich K, Asahina A, Gu Y, Beason J, Rozzo S, Tyring S. Leonardi C, et al. Among authors: reich k. Am J Clin Dermatol. 2011 Oct 1;12(5):321-37. doi: 10.2165/11587890-000000000-00000. Am J Clin Dermatol. 2011. PMID: 21834597 Review.

8

An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up.

Reich K, Papp KA, Griffiths CE, Szapary PO, Yeilding N, Wasfi Y, Ott E, Hsu MC, Lebwohl M, Gordon KB; PHOENIX 1, PHOENIX 2, and ACCEPT investigators. Reich K, et al. J Drugs Dermatol. 2012 Mar;11(3):300-12. J Drugs Dermatol. 2012. PMID: 22395580 Clinical Trial.

9

Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab' certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension.

Reich K, Ortonne JP, Gottlieb AB, Terpstra IJ, Coteur G, Tasset C, Mease P. Reich K, et al. Br J Dermatol. 2012 Jul;167(1):180-90. doi: 10.1111/j.1365-2133.2012.10941.x. Epub 2012 Jun 11. Br J Dermatol. 2012. PMID: 22413944 Clinical Trial.

10

Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up.

Papp KA, Griffiths CE, Gordon K, Lebwohl M, Szapary PO, Wasfi Y, Chan D, Hsu MC, Ho V, Ghislain PD, Strober B, Reich K; PHOENIX 1 Investigators; PHOENIX 2 Investigators; ACCEPT Investigators. Papp KA, et al. Among authors: reich k. Br J Dermatol. 2013 Apr;168(4):844-54. doi: 10.1111/bjd.12214. Br J Dermatol. 2013. PMID: 23301632

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

582 results

Search Page